NSAIDs were associated with more adverse CV events than was colchicine.
Guidelines recommend that when patients with gout start urate-lowering therapy, they also begin anti-inflammatory prophylaxis consisting of nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine for 3 to 6 months. Although cardiovascular (CV) risk associated with NSAIDs is well established, comparative safety data between colchicine and NSAIDs in the context of anti-inflammatory prophylaxis is limited.
In this study, researchers used a Canadian registry to examine CV outcomes among adults with gout who had newly initiated allopurinol and NSAIDs or colchicine. Patients were matched by age, year of drug initiation, and cardiovascular comorbidities; the follow-up period was defined based on NSAID and colchicine dispensing.
The primary outco…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose